Riociguat for the treatment of pulmonary arterial hypertension: A long-term extension study (patent-2)

European Respiratory Journal

Volumn 45, Issue 5, 2015, Pages 1303-1313

  Rubin, Lewis J ^a   Galié, Nazzareno ^b   Grimminger, Friedrich ^c,d   Grünig, Ekkehard ^e   Humbert, Marc ^f,g,h   Jing, Zhi Cheng ⁱ   Keogh, Anne ^j   Langleben, David ^k   Fritsch, Arno ^l   Menezes, Flavia ^m   Davie, Neil ^l   Ghofrani, Hossein Ardeschir ^c,d,n  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c JUSTUS LIEBIG UNIVERSITY GIESSEN   (Germany)

^d Department of German Center of Lung Research ^*  (Germany)

^e UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^f UNIVERSITÉ PARIS SACLAY   (France)

^g BICÊTRE HOSPITAL   (France)

^h CENTRE CHIRURGICAL MARIE LANNELONGUE   (France)

ⁱ PEKING UNION MEDICAL COLLEGE   (China)

^j ST VINCENT S HOSPITAL   (Australia)

^k MCGILL UNIVERSITY   (Canada)

^l BAYER PHARMA AG   (Germany)

^m Bayer HealthCare Pharmaceuticals   (Brazil)

ⁿ IMPERIAL COLLEGE LONDON   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; RIOCIGUAT; ANTIHYPERTENSIVE AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; GUANYLATE CYCLASE; PROSTAGLANDIN; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ADULT; ARTICLE; CONTROLLED STUDY; COUGHING; DIARRHEA; DISEASE COURSE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; DYSPNEA; EPISTAXIS; EXERCISE; FAINTNESS; FEMALE; FOLLOW UP; FUNCTIONAL STATUS; HEADACHE; HEMOPTYSIS; HUMAN; LONG TERM CARE; LUNG HEMORRHAGE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OPEN STUDY; PERIPHERAL EDEMA; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RHINOPHARYNGITIS; SYSTOLIC BLOOD PRESSURE; THORAX PAIN; UPPER RESPIRATORY TRACT INFECTION; VOMITING; AGED; CHEMISTRY; CLINICAL TRIAL; EXERCISE TEST; HYPERTENSION, PULMONARY; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; PATIENT SAFETY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TIME FACTOR; TREATMENT OUTCOME;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; DOUBLE-BLIND METHOD; ENDOTHELIN RECEPTOR ANTAGONISTS; EXERCISE TEST; FEMALE; FOLLOW-UP STUDIES; GUANYLATE CYCLASE; HUMANS; HYPERTENSION, PULMONARY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PATIENT SAFETY; PROSTAGLANDINS; PYRAZOLES; PYRIMIDINES; QUALITY OF LIFE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84929008935     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00090614     Document Type: Article

References (19)

1. Galiè N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009; 30: 2493-2537.
2. McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document: ACCF/AHA 2009 expert consensus document on pulmonary hypertension. Circulation 2009; 119: 2250-2294.
3. Galiè N, Corris PA, Frost A, et al. Updated treatment algorithm of pulmonary arterial hypertension. J Am Coll Cardiol 2013; 62; Suppl., D60-D72.
4. O'Connell C, O'Callaghan DS, Humbert M. Novel medical therapies for pulmonary arterial hypertension. Clin Chest Med 2013; 34: 867-880.
5. Grimminger F, Weimann G, Frey R, et al. First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension. Eur Respir J 2009; 33: 785-792.
6. Ghofrani HA, Galiè N, Grimminger F, et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 2013; 369: 330-340.
7. Ghofrani HA, D'Armini AM, Grimminger F, et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med 2013; 369: 319-329.
8. Barst RJ, McGoon M, McLaughlin V, et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2003; 41: 2119-2125.
9. Barst RJ, Galie N, Naeije R, et al. Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil. Eur Respir J 2006; 28: 1195-1203.
10. Olschewski H, Simonneau G, Galiè N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002; 347: 322-329.
11. Rubin LJ, Badesch DB, Fleming TR, et al. Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: The SUPER-2 study. Chest 2011; 140: 1274-1283.
12. Tio D, Leter E, Boerrigter B, et al. Risk factors for hemoptysis in idiopathic and hereditary pulmonary arterial hypertension. PLoS One 2013; 8: E78132.
13. Zylkowska J, Kurzyna M, Pietura R, et al. Recurrent hemoptysis: An emerging life-threatening complication in idiopathic pulmonary arterial hypertension. Chest 2011; 139: 690-693.
14. Henkens IR, Hazenoot T, Boonstra A, et al. Major bleeding with vitamin K antagonist anticoagulants in pulmonary hypertension. Eur Respir J 2013; 41: 872-878.
15. Fadel E, Wijtenburg E, Michel R, et al. Regression of the systemic vasculature to the lung after removal of pulmonary artery obstruction. Am J Respir Crit Care Med 2006; 173: 345-349.
16. Benza RL, Seeger W, McLaughlin VV, et al. Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: The treprostinil sodium inhalation used in the management of pulmonary arterial hypertension (TRIUMPH) study open-label extension. J Heart Lung Transplant 2011; 30: 1327-1333.
17. Oudiz RJ, Brundage BH, Galie N, et al. Tadalafil for the treatment of pulmonary arterial hypertension: A double-blind 52-week uncontrolled extension study. J Am Coll Cardiol 2012; 60: 768-774.
18. Sitbon O, Badesch DB, Channick RN, et al. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: A 1-year follow-up study. Chest 2003; 124: 247-254.
19. Pulido T, Adzerikho I, Channick RN, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 2013; 369: 809-818.